TLDR The document corrects a mistake by stating that pimecrolimus, not tacrolimus, is the drug that concentrates in the skin.
The document acknowledges an error in a previously published article titled "Pimecrolimus. Pharmacology and preclinical studies" in the journal Piel, specifically in the caption of figure 8. The error pertained to the incorrect naming of a drug; where "tacrolimus" was mentioned, it should have been "pimecrolimus." The corrected figure caption is provided, indicating that pimecrolimus, not tacrolimus, preferentially distributes in the skin according to pharmacokinetic data from an experimental study involving oral doses of 25 mg/kg in rats, with concentrations measured 6 hours after the second dose. The figure shows the tissue concentration ratio of pimecrolimus to tacrolimus.
4 citations,
September 2014 in “Elsevier eBooks” Use some skin medications with caution during pregnancy; avoid strong steroids, certain eczema treatments, and systemic retinoids, but many topical treatments and nasal sprays are safe.
159 citations,
March 2014 in “Journal of The American Academy of Dermatology” Some skin medications are safe during pregnancy and breastfeeding, but others can harm the baby and should be avoided.
[object Object] 
3 citations,
December 2022 in “Cells” Cannabinoids like CBD and THC may help treat non-cancer skin diseases, but more research is needed.
73 citations,
March 2014 in “Journal of The American Academy of Dermatology” Most dermatologic medications are safe during pregnancy and breastfeeding, but some should be avoided due to potential risks.
4 citations,
March 2023 in “Current Oncology” Scalp cooling is the only FDA-approved method to prevent hair loss from chemotherapy, but other treatments like minoxidil and PRP are being tested.
